Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 0.72 |
| ▸ | EDNRB | P24530 | 11/20 | 0.65 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | DHPS | P49366 | 1/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.64 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592200 | 0.94 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL6956122 | 0.93 | EDNRA (0.68) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7445575 | 0.91 | EDNRA (0.66) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7305595 | 0.91 | EDNRA (0.74) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL6957198 | 0.90 | EDNRA (0.66) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL8327615 | 0.89 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL795564 | 0.88 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7600932 | 0.88 | EDNRA (0.70) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL8321011 | 0.87 | EDNRA (0.76) | EDNRAEDNRB | |
| SCHEMBL6972701 | 0.85 | EDNRA (0.60) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885ABCC3 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.